Osteogenesis imperfecta type IV: Prenatal molecular diagnosis and genetic counseling in a pregnancy carried to full term with favorable outcome  by Chen, Chih-Ping et al.
Available online at www.sciencedirect.comTaiwanese Journal of Obstetrics & Gynecology 51 (2012) 271e275
www.tjog-online.comCase Report
Osteogenesis imperfecta type IV: Prenatal molecular diagnosis and genetic
counseling in a pregnancy carried to full term with favorable outcome
Chih-Ping Chen a,b,c,d,e,f,g,*, Shuan-Pei Lin c,h,i, Yi-Ning Su j, Schu-Rern Chern c, Ming-Huei Lin b,
Jun-Wei Su b,k, Wayseen Wang c,l
aDepartment of Medicine, Mackay Medical College, New Taipei City, Taiwan
bDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
cDepartment of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
dDepartment of Biotechnology, Asia University, Taichung, Taiwan
e School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan
f Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei, Taiwan
gDepartment of Obstetrics and Gynecology, School of Medicine, National Yang-Ming University, Taipei, Taiwan
hDepartment of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
iMackay Medicine, Nursing and Management College, Taipei, Taiwan
jDepartment of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan
kDepartment of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan
lDepartment of Bioengineering, Tatung University, Taipei, Taiwan
Accepted 17 February 2012AbstractObjective: To present molecular diagnosis and genetic counseling for osteogenesis imperfecta (OI) type IV in a pregnancy carried to term with
favorable outcome.
Case Report: A 34-year-old, primigravid woman was referred for genetic counseling in the second trimester because of advanced maternal age
and a positive family history of OI type IV. Her husband had a weight of 40 kg and a height of 145 cm. Her husband had normal sclerae,
moderate short stature and osteopenia, and had sustained multiple fractures with minimal trauma since childhood. The husband and his relatives
including his mother, aunt, uncle, sister and nephew had suffered from OI type IV. Molecular analysis of the affected individuals in the family
revealed a G to T change at position c.2197 (c.2197G>T, GGT>TGT) of the exon 37 in the COL1A2 gene leading to a change of glycine at
codon 733 to cysteine (G733C). Cytogenetic analysis of cultured amniocytes revealed a karyotype of 46,XY. Molecular analysis of uncultured
amniocytes revealed a missense mutation of G733C in COL1A2. Level II ultrasound at 23 weeks of gestation revealed significant shortness of the
limbs. Small stature for gestation age was obvious in the third trimester. At 37 weeks of gestation, a fetal ultrasound showed curvature of the
femurs. A cesarean section was performed at 38 weeks of gestation, and a male baby was delivered uneventfully. The baby had normal sclerae,
a body weight of 2190 g (< 5th centile) and a body length of 46 cm (< 5th centile). X-rays showed thin clavicles and short curved femurs but no
bony fractures. No fractures were noted at the age of 1 month.
Conclusion: The present case adds to previous examples of favorable outcome in pregnancies with non-lethal forms of OI.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Fig. 1. Molecular analysis of the father and the fetus shows a G to T change at
position c.2197 (c.2197G>T, GGT/TGT) of the exon 37 in the COL1A2
gene leading to a change of glycine at codon 733 to cysteine (G733C).
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Osteogenesis imperfecta (OI) is a genetic disorder of bone
development caused by defective collagen synthesis that
results in increased bone fragility, osteopenia and other
connective-tissue manifestations such as blue sclerae, denti-
nogenesis imperfecta, hyperlaxity of ligaments and skin, and
hearing loss [1,2]. The incidence of OI varies between
1:20,000 and 1:60,000 births, and maternal OI has been esti-
mated to occur once in every 25,000e30,000 pregnancies
[3,4].
Most patients with autosomal dominant OI have mutation in
either COL1A1 (OMIM 120150) or COL1A2 (OMIM 120160).
However, mutations in other genes such as FKBP10 (OMIM
607063), CRTAP (OMIM 605497), LEPRE1 (OMIM 610339),
PPIB (OMIM 123841), SERPINH2 (OMIM 600943), SP7
(OMIM 606633) and SERPINF1 (OMIM 172860) can also
cause autosomal recessive OI.
OI type I to type IV have been inherited in an autosomal
dominant pattern. OI type I (OMIM 166200) is caused by
heterozygous mutation in COL1A1. OI type II (OMIM
166210), type III (OMIM 259420) and type IV (OMIM
166220) are caused by heterozygous mutation in either
COL1A1 or COL1A2. OI type V (OMIM 610967) is inherited
in an autosomal dominant pattern, but the causative gene is
unknown.
OI type VI to type XII have been inherited in an autosomal
recessive pattern. OI type VI (OMIM 610968) can be caused
by homozygous mutations in FKBP10, OI type VII (OMIM
610682) is caused by homozygous or compound heterozygous
mutations in CRTAP, OI type VIII (OMIM 610915) is caused
by homozygous or compound heterozygous mutations in
LEPRE1, OI type IX (OMIM 259440) can be caused by
homozygous mutations in PPIB, OI type X (OMIM 613848)
can be caused by homozygous mutations in SERPINH2, OI
type XI (OMIM 613849) can be caused by homozygous
mutations in SP7, and OI type XII (OMIM 613982) can be
caused by homozygous mutations in SERPINF1.
Currently, early prenatal diagnosis of OI in at-risk preg-
nancies is possible by preimplantation genetic diagnosis,
chorionic villus sampling (CVS) or amniocentesis using
molecular genetic techniques if the mutated gene has been
identified in affected individuals in the family. Here, we report
our experience of application of prenatal molecular genetic
testing on uncultured amniocytes in the second trimester for
prenatal diagnosis of OI type IV in a Taiwanese family. The
parents elected to carry the pregnancy to term, and a male
baby was delivered with mild OI and favorable outcome.
Case report
A 34-year-old, primigravid woman was referred for genetic
counseling in the second trimester because of advanced
maternal age and a positive family history of OI type IV. The
woman had a body weight of 62 kg and a height of 162 cm,
whereas, her husband had a weight of 40 kg and a height of
145 cm. Her husband had normal sclerae, moderate shortstature and osteopenia, and had sustained multiple fractures
with minimal trauma since childhood. The husband and his
relatives including his mother (135 cm in height), aunt
(130 cm), uncle (150 cm), sister (135 cm) and nephew had
suffered from OI type IV. All had moderate short stature and
white sclerae. Molecular analysis of the husband in the family
revealed a G to T change at position c.2197 (c.2197G>T,
GGT>TGT) of the exon 37 in the COL1A2 gene leading to
a change of glycine at codon 733 to cysteine (G733C) (Fig. 1).
Prenatal ultrasound examination at 19 weeks of gestation
revealed a fetus with no skeletal abnormalities and a biparietal
diameter (BPD), an abdominal circumference (AC) and
a femur length (FL) equivalent to 19 weeks. The woman
underwent amniocentesis at 19 weeks of gestation. Cytoge-
netic analysis revealed a karyotype of 46,XY. Molecular
analysis of uncultured amniocytes revealed a missense muta-
tion of G733C in COL1A2 (Fig. 1). Level II ultrasound at 23
weeks of gestation revealed significant shortness of the limbs
with the measurements of the humerus of 3.67 cm (22 weeks),
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femur of 3.5 cm (21 weeks), tibia of 3.24 cm (21 weeks) and
fibula of 3.13 cm (21 weeks). After genetic counseling of
possible phenotypic variability in OI with the parents, the
parents elected to carry the pregnancy to term. Small stature
for gestation age was obvious in the third trimester. At 37
weeks of gestation, the fetal ultrasound showed a BPD of
8.6 cm (34 weeks), an AC of 29.7 cm (35 weeks), an FL of
5.8 cm (31 weeks), and curvature of the femurs (Fig. 2). A
cesarean section was performed at 38 weeks of gestation, and
a male baby was delivered uneventfully. The baby had normal
sclerae, a body weight of 2190 g (< 5th centile), a body length
of 46 cm (< 5th centile), a head circumference of 32.5 cm (5th
centile), and a chest circumference of 29.5 cm (< 5th centile).
X-rays showed thin clavicles and short curved femurs but no
bony fractures (Fig. 3). The baby was doing well, and no
fractures were noted at the age of 1 month.Fig. 3. Postnatal radiograph shows short curved femurs and thin clavicles but
no bony fractures.Discussion
OI is clinically and genetically heterogeneous with variable
clinical features in different types ranging from nearly
asymptomatic manifestations with normal stature and mild
fractures to symptomatic manifestations with very short
stature, severe skeletal deformities, multiple fractures and
mobility impairment or worse, perinatal lethality. OI types I
and IV are mild forms of OI caused by mutation in either
COL1A1 or COL1A2. OI type I is characterized by blue
sclerae, normal height or mild short stature and a premature
stop codon in COL1A1, whereas, OI type IV is characterized
by moderately short stature, grayish or white sclerae, denti-
nogenesis imperfecta, adult-onset hearing loss and glycine
substitutions in COL1A1 or COL1A2 [1,2]. In the present case
the fetus and father had white sclerae, moderate short stature,
a glycine substitution in COL1A2 and OI type IV.
In the second trimester, only the severe and lethal forms of
OI can be detected by ultrasound before 20 weeks of gestation.
The mild forms of OI are usually detected in late gestation
when skeletal deformities occur. The diagnosis of OI type I byFig. 2. Prenatal ultrasound at 37 weeks of gestation shows curvature of the
femur.ultrasound is difficult and is only rarely apparent due to
femoral bowing [5]. The diagnosis of OI type IV is usually not
apparent by ultrasound until after 20 weeks of gestation when
femoral bowing and short limbs become obvious [5]. In cases
of mild forms of familial OI, early prenatal diagnosis is
possible only through prenatal genetic testing by CVS or
amniocentesis.
Clinical cases of prenatally detected OI carried to term have
been reported. Phillips et al [6] reported the first prenatal
diagnosis of OI type III with abnormal ultrasound findings
suggestive of OI at 14.8 weeks of gestation and definitive
ultrasound findings of OI at 17 weeks in a pregnancy with OI
type III in the mother. The mother was 106 cm tall and had
severe scoliosis, gray sclerae and severe bowing and short-
ening of the lower extremities. After genetic counseling, the
parents elected to continue the pregnancy, and a baby was
delivered at 34 weeks of gestation by cesarean section with
a body weight of 1685 g (35e50th centile), a length of 37.5 cm
(10th centile), a head circumference of 30.5 cm (25e50th
centile), a broad forehead, blue sclerae, a soft skull and
bilaterally bowed extremities but no obvious fractures. Zolezzi
et al [7] reported prenatal ultrasound diagnosis of short limbs
and multiple fractures in a fetus at 25 weeks of gestation in
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grandmother. Termination of pregnancy was proposed by the
obstetrician, but the parents elected to continue the pregnancy
after genetic counseling and awareness of familial OI type IV.
A splicing site mutation of IVS26þ3 A>G was found in the
COL1A2 gene in the father and the paternal grandmother. The
baby was delivered at term by cesarean section with a weight
of 2240 g, a length of 39 cm, a head circumference of 32.4 cm,
bowing lower limbs and talipes varus but no bony fractures. At
the age of 6 months, the affected neonate was of short stature
with brachycephaly, round face, and shortening and bowing
limbs, but normal psychomotor development. In this case,
there was intrafamilial clinical variability. The father was
156 cm tall, the paternal mother was 155 cm tall, and both
presented only subtle clinical and radiological signs of OI.
Ries et al [8] reported prenatal molecular diagnosis of
a nonsense mutation of R848X in the COL1A1 gene by CVS in
a pregnancy because of familial OI type I and the previous
aneuploidy of trisomy 18. The fetus was found to carry the
same mutation as the affected father. After genetic counseling
of possible phenotypic variability in OI with the parents, the
parents elected to carry the pregnancy to term. A male baby
was born at term in an uncomplicated delivery with a fractured
clavicle, bowed right tibia and blue sclerae. No additional
fractures were noted at 12 months of age. The father was
163 cm tall and manifested blue sclerae and shortening of the
right leg due to poorly healed fracture and osteopenia. Chen
et al [9] reported prenatal ultrasound diagnosis of shortening
femurs at 28 weeks of gestation in a pregnancy with maternal
OI type I. The mother was 148 cm tall and had blue sclerae,
shortening of the legs as a result of old fractures, and
a missense mutation of G844D in the COL1A2 gene. The
parents refused any prenatal molecular genetic diagnosis for
OI and decided to carry the pregnancy to term. A cesarean
section was performed at 37 weeks of gestation, and a 2358 g
female baby was delivered uneventfully with a length of
47 cm, short curved femurs, blue sclerae, but no bony frac-
tures. Molecular analysis showed that the baby had the same
mutation as the mother. Coors and Townsend [10] reported
prenatal ultrasound diagnosis of a fetus with multiple
congenital fractures at 21 weeks of gestation consistent with
the diagnosis of OI type II. Despite of genetic counseling of
the lethality of OI type II and a recommendation of vaginal
delivery for the fetus, the woman elected to carry the preg-
nancy to term and chose cesarean delivery. The baby survived
for only several days, and X-rays confirmed the severity of OI.
The mother felt that she had done everything appropriate for
her infant. Robyr et al [11] reported prenatal ultrasound
diagnosis of moderate bowing of the long bones in a preg-
nancy with paternal genu varum and kyphscoliosis. The
pregnancy was carried to term with a baby having bowed
femur and tibia. Parasuraman et al [4] reported prenatal
ultrasound diagnosis of bowed right femur at 22 weeks of
gestation and bowed left tibia at 23 weeks of gestation in
a pregnancy with maternal OI type III. The mother decided to
continue the pregnancy, and a 1708 g affected baby was
delivered by elective cesarean section at 34 weeks of gestation.Current practice of prenatal diagnosis and genetic coun-
seling of familial OI should include more information based
on genotype, phenotype, previous reports, prenatal ultrasound
findings, intrafamilial variability, detailed family history and
perspectives of treatment [9,12]. Mutation analysis of the
family is important for genetic counseling of OI. In familial
autosomal dominant OI, the recurrence risk for OI is estimated
to be 50%. However, severe and lethal forms of OI may result
from parental mosaicism for dominant mutations in COL1A1
or COL1A2 with intrafamilial variability and mild or no
symptom in the parent [13,14]. Therefore, in cases of parental
mosaicism, the recurrence risk for autosomal dominant OI is
variable and may not be as high as 50%. In cases of lethal
forms of OI, Pyott et al [15] suggested that in the absence of
parental somatic mosaicism or recessive inheritance, the risk
of recurrence is below 0.1%; in the presence of parental
mosaicism, the risk of recurrence can be up to 50%; and in the
presence of carriers of a recessive mutation in both parents, the
risk of recurrence is 25%. In cases of unaffected parents with
parental gonadal mosaicism, an empirical risk of recurrence
risk ranges from 1% to 3% [12,16]. Recent advances in ther-
apies with bisphosphonates, injection of human growth
hormone and bone marrow transplantation have shed light on
effective treatment of OI [2,17]. On the other hand, cesarean
delivery may not protect against fractures in infants with OI,
and obstetricians should reserve cesarean section for usual
obstetric indications [18].
In summary, we present molecular diagnosis and genetic
counseling of OI type IV in a pregnancy carried to term with
favorable outcome. Our case adds to the examples of favorable
outcome in pregnancies with non-lethal forms of OI.Acknowledgments
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